Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DEA Decriminalizes CBD Oil
We in the community have always known the value of cannabinoids, and the U.S. government agrees as hemp CBD was legalized for growth and consumption by 2014. With less than .3% THC, our products have all the health benefits without any risk of psychological effects. And now, safe distribution of Hemp CBD is easier than ever. In 2018, the DEA re-classified CBD with less than .1% THC as a “Schedule V” and thus non-addicting drug. That means safer distribution, legal growing, and more tests that will reveal the benefits of the cannabis plant. With cannabis CBD gaining traction for its health benefits, it’s easier to enjoy CBD products than ever.
SOURCE: https://usmj.com
Most likely after the bell
Volume at 0.1779 !!!!!
KALY - Kali Extracts Announces Patented Cannabis Extracts Targeting $170 Million In Pharmaceutical Treatments
Hold tight boys and girls, DO NOT PLAY INTO THE MMs HANDS. DO NOT SELL !!!
B. The Limit Order Display Rule
The Limit Order Display Rule, Rule 11Ac1-4, which became effective in January 1997, and was fully implemented by August 1997, generally requires market makers to display customer limit orders that: (1) are priced better than the market-maker's quote, or (2) add to the size of a market maker's quote when the market maker is at the best price in the market, known as the National Best Bid or Offer ("NBBO").2 A market maker does not have to display any limit orders that it immediately executes or sends to another market maker or a qualified ECN (electronic communication network) for handling.3 The improving limit order must continue to be displayed until it is executed, rerouted or a new improving quote is displayed.
The purpose of the Limit Order Display Rule is to provide transparency by allowing the market to see improving customer limit orders and consequently, enhancing execution quality, and encouraging liquidity.
Something tells me that some folks aren't playing by the SEC rules. Play back the last half hr of Fridays session and you will see what I mean.
BINGO !!!!!!!
OTCMKTS:GNBT - News Headlines for Generex Biotechnology ...
https://www.marketbeat.com/stocks/OTCMKTS/GNBT/news/
Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th
GlobeNewswire•April 9, 2019
DALLAS, April 09, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today announced an online presentation scheduled next week for Wednesday, April 17th, where management will provide details on its patented cannabis extract treatments targeting a $170 million pharmaceutical market opportunity currently under development. The company has recently announced ongoing cannabis extract research and development targeting four specific health issues: Chronic Obstructive Pulmonary Disease (COPD); Type 2 Diabetes; Cancer Pain Management, and Epilepsy. The market for Type 2 Diabetes is expected to be a $64 billion market by 2026. The market for COPD treatment is anticipated to reach $14 billion by 2025. The overall pain management treatment market is anticipated to reach $83 billion by 2024. The market for epilepsy treatment is anticipated to reach $9 billion by 2022.
Beyond the four specific cannabis therapies currently in various stages of research and development, KALY has a number of additional target therapies in its research pipeline which will be highlighted in the April 17th presentation.
Between now and the April 17th presentation, KALY plans to mention several key updates regarding their business operations separate from the cannabis extract pharmaceutical research and development business. These announcements will be further incorporated into the upcoming April 17th presentation. The announcements and supplementary presentation material pertains to where KALY is generating revenue from its patented cannabis extraction process delivering proprietary extracts for infusion into non-pharmaceutical commercial products. For instance, KALY recently announced finalizing its all new 25 mg CBD Extract formulation for beverage infusion. KALY’s patented extraction process already produces a 10 mg CBD formulation for Puration, Inc.’s (PURA) (“PURA”) leading EVERx CBD Sports Water. Management plans to include in the presentation updates on how the 25 mg CBD Extract formulation pertains to KALY and PURA’s contract to produce a private labeled CBD water for Generex Biotechnology, Corp. (GNBT).
KALY is a health and wellness company set to generate revenue from its patented cannabis extraction technology through overlapping go-to-market strategies. In addition to developing pharmaceutical products internally and through partnerships, KALY is utilizing is patented cannabis extraction process to develop numerous wellness products both internally and through partnerships. The first revenue generating contracts signed in December of 2018 will be reflected in the company’s upcoming annual report.
To learn more about the company visit https://www.kali-extracts.com/
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and as such, may involve risks and uncertainties. These forward looking statements relate to, amongst other things, current expectation of the business environment in which the company operates, potential future performance, projections of future performance and the perceived opportunities in the market. The company's actual performance, results and achievements may differ materially from the expressed or implied in such forward-looking statements as a result of a wide range of factors.
And PANIC SELLING. Played right into the MMs hands. This stock is so volatile it could rebound in a heartbeat. I normally use a trail stop but when looking at this chart there was really no set of indicators to follow especially the 30 day chart. It will rebound and those stop losses will have backfired on most !
Stop losses
Folks, a market maker is a firm who quotes both a buy and a sell price in a financial instrument or commodity, hoping to make a profit on the turn or the bid/offer spread. In other words MMs are banks and other large firms. There is a way to beat them if you understand their strategy's !!!
Do you not know how to read candlesticks and wicks? They are a dead giveaway of the activity !!!
I am NOT trying to bash anybody, in fact I want to see everybody succeed but there is so much uneducated information in these forums.
Margin Trading: The Dreaded Margin Call
As the concepts of maintenance margin and margin call are vital to understanding how a margin account works, we demonstrate these with an example below.
Let’s say you open a margin account with $5,000 of your own money and $5,000 borrowed from your brokerage firm as a margin loan. You purchase 200 shares of a marginable stock at a price of $50; under Regulation T, you borrow 50% of the purchase price. Assume that the maintenance margin requirement (MMR) is 30%. (Related: What happens if I cannot pay a margin call? and Do you have to sell your stocks when you get a margin call?)
The Table below shows the changes in the margin account as the stock price fluctuates over time. Note that as the current stock price falls below the purchase price, account equity gets steadily eroded, culminating in a margin call when the shares are trading at $35.
What is the exact stock price below which a margin call will be triggered? This occurs when Account Equity equals the Maintenance Margin Requirement. Mathematically this translates into the stock price at which:
Account Value = (Margin Loan) / (1-MMR)
In this example, a margin call will be triggered when the account value falls below $7,142.86 (i.e. margin loan of $5,000 / (1 – 0.30), which equates to a stock price of $35.71.
When the price of the stock that was purchased at $50 falls to $35, it triggers a margin call of $100. You therefore have one of three choices to rectify your margin deficiency of $100:
Deposit $100 cash in your margin account, or
Deposit marginable securities worth $142.86 in your margin account, which will bring your account value back up to $7,142.86, or
Liquidate stock worth $333.33; with the proceeds used to reduce the margin loan; at the current market price of $35, this works out to 9.52 shares, rounded off to 10 shares.
The value of shares to be liquidated can be calculated by the following relationship:
Liquidation Value = Account Value – (Account Equity / MMR)
Thus, Liquidation Value in this case is: $7,000 – ($2,000 / 0.30) = $333.33
When the stock price falls to $30, the margin deficiency increases to $800. The choices you have to meet your margin call are:
Deposit $800 cash in your margin account, or
Deposit marginable securities worth $1,142.86 in your margin account, which will bring your account value back up to $7,142.86, or
Liquidate stock worth $2,666.67; with the proceeds used to reduce the margin loan; at the current market price of $30, this works out to 88.89 shares, rounded off to 89 shares.
Example of Maintenance Margin and Margin Call
*MMR = Maintenance Margin Requirement
If for some reason, you are not aware of the margin call or cannot meet the margin call, your broker has the right to liquidate stock in the amounts shown without further notice to you.
https://www.investopedia.com/university/margin/margin2.asp
KALY has the potential to run from its $0.01 PPS level to $0.10 in the near term.
Key word "In the near term).
Very well run company with great management and VERY undervalued !!!!
In consolidation mode all morning. Holding nicely in the .02 range.
Remember, unlike many over the OTC companies that focus on only one product Kali has multiple products in their line up. A HUGE advantage over many of the companies with exceptional potential !
Today was nothing more than a SWING LOW day meaning there was more sellers than buyers. This is very normal after an 8 day uptrend move and expected. With that said KALY is still in an uptrend mode! There was absolutely no bad news today to cause this but the shortsellers doing everything they can to cover their calls. I'm a trend trader and have seen this action more times than I can count. Expecting a STRONG rally in the coming days !
GETTING READY FOR HUGE CRASH to 1.50!!
CRASH DOWN TO 1.90
Please explain your technical analysis for these statements. I see this extremely well run company continue its upward trend.
Why?
1) it has maintained an upward trend the entire yr. Especially the past 6
months.
2) It just broke an all time high
3) It's gains are as follows
- Per week 43.71%
- Perf Month 87.50%
- Perf Quarter 88.24%
- Perf Half Y 79.10%
- Perf Year 71.43%
- Perf YTD 101.68% !!!
4) Volume 572,170
5) And here's the doozy ..... Short Float 0.06%
6) LET ME REPEAT THAT .... Short Float 0.06%
Less than 1%, I love seeing that and am very very bullish on this company. Nothing evident shows a crash whatsoever, in fact I'm seeing quite the opposite. With all the new contracts they were recently awarded with and the simple fact that they have outperformed nearly every other company in it's sector all year suggests nothing less that this trend will continue.
Looking forward to your response :)
Yes I saw that as soon as the 8-K filing was released. It's just a slightly longer version of it.
Item 8.01
The Company believes that the issues raised by the CRL, which were related to the concerns over reproducible dose delivery, can be addressed, and expects to meet and work with FDA to gain a full understanding of the Agency’s requirements for approval.
It will continue to spiral down until EVOK comes out with some sort of positive statement/news which I expected to be done already. Looking at the 3 yr chart this company has been been pretty much flat lining with an average of 2.38. The 3 yr low is .77 which we're sitting at right now. I cut my losses yesterday at 20% (ouch !!!) but it could have been much worse. I'm expecting it to bottom out in the mid .60s unless EVOK comes out with a positive formal statement. Easy fix? ....yes. Question is how long will it take! We're talking Biotech here. There is a reason it is one of the most volatile sectors in the market. Not bashing the stock just stating reality, all IMO of course.
Lots of shorts and panic selling is all. Once the shock wears off the only place to go is up. Support level right now is 90, resistance is 92. I'm not that concerned, will probably swing this for a few weeks.
ADMA Biologics Inc
ADMA 13.98%
awaits FDA nod for its BLA for RI-002, which is being evaluated as a treatment option for Primary Immune Deficiency Disease, or PIDD. The PDUFA date is scheduled for April 2.
https://www.benzinga.com/general/biotech/19/03/13443439/the-week-ahead-in-biotech-conferences-pdufa-dates-clinical-trials-ear
Target Price $10.00 with a Buy rating
https://www.finviz.com/quote.ashx?t=adma
My apolgy for multiple posts. Kept getting error messages from IHub each time I clicked on submit. Can the moderator please remove all but one?
Thank you!
https://www.benzinga.com/general/biotech/19/03/13335075/zynerba-pharmaceuticals-adds-autism-digeorge-syndrome-to-pipeline
Zynerba Pharmaceuticals Adds Autism, DiGeorge Syndrome To Pipeline
Zynerba Pharmaceuticals Inc
ZYNE 1.26%
beat the consensus estimate for its fourth-quarter loss Monday and provided some highlights from its ongoing and upcoming trials.
What Happened
The company posted revenue of just $86,000 for the quarter ended Dec. 31, which was the only revenue recorded for the entire year. At the same time, Zynerba's net loss narrowed from $8.12 million or 60 cents per share a year earlier to $7.79 million or 44 cents per diluted share.
Zynerba registered an increase in general and administrative expenses during the fourth quarter from $2.38 million a year earlier to $3.26 million. Research and development costs declined from $5.83 million to $4.88 million. In this way, Zynerba's total operating expenses inched down from $8.2 million to $8.13 million.
The company ended the quarter with cash and cash equivalents of $59.8 million, down from $62.5 million recorded at the end of December 2017.
Why It's Important
Zynerba is conducting a number of studies evaluating its CBD-based transdermal gel candidate ZYN002, or Zygel.
The company said it is in the process of enrolling patients for its CONNECT-FX study that evaluates the efficacy and safety of Zygel in patients ages 3-17 with Fragile X syndrome. It expects to report top-line results from the study in the second half of 2019 and to submit a New Drug Application in the first half of 2020, with the potential for approval by the end of the year.
The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian, Alan Brochstein and many others.
Zynerba said it completed enrollment in BELIEVE 1, an open-label, multidose Phase 2 trial that evaluates Zygel in children and adolescents with developmental and epileptic encephalopathies. The top-line data from the study are expected in the third quarter of 2019.
Zynerba also said it initiated a study for Zygel administered to children and adolescents with autism spectrum disorder, and plans to initiate a study for Zygel in DiGeorge syndrome in the second quarter of 2019.
What's Next
Zynerba anticipates that its cash and cash equivalent position is sufficient to fund its operations and capital requirements beyond the expected submission and potential approval of ZYN002 in Fragile X Syndrome patients and into the first quarter of 2021.
Zynerba Pharmaceuticals Adds Autism, DiGeorge Syndrome To Pipeline
Zynerba Pharmaceuticals Inc
ZYNE 1.26%
beat the consensus estimate for its fourth-quarter loss Monday and provided some highlights from its ongoing and upcoming trials.
What Happened
The company posted revenue of just $86,000 for the quarter ended Dec. 31, which was the only revenue recorded for the entire year. At the same time, Zynerba's net loss narrowed from $8.12 million or 60 cents per share a year earlier to $7.79 million or 44 cents per diluted share.
Zynerba registered an increase in general and administrative expenses during the fourth quarter from $2.38 million a year earlier to $3.26 million. Research and development costs declined from $5.83 million to $4.88 million. In this way, Zynerba's total operating expenses inched down from $8.2 million to $8.13 million.
The company ended the quarter with cash and cash equivalents of $59.8 million, down from $62.5 million recorded at the end of December 2017.
Why It's Important
Zynerba is conducting a number of studies evaluating its CBD-based transdermal gel candidate ZYN002, or Zygel.
The company said it is in the process of enrolling patients for its CONNECT-FX study that evaluates the efficacy and safety of Zygel in patients ages 3-17 with Fragile X syndrome. It expects to report top-line results from the study in the second half of 2019 and to submit a New Drug Application in the first half of 2020, with the potential for approval by the end of the year.
The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian, Alan Brochstein and many others.
Zynerba said it completed enrollment in BELIEVE 1, an open-label, multidose Phase 2 trial that evaluates Zygel in children and adolescents with developmental and epileptic encephalopathies. The top-line data from the study are expected in the third quarter of 2019.
Zynerba also said it initiated a study for Zygel administered to children and adolescents with autism spectrum disorder, and plans to initiate a study for Zygel in DiGeorge syndrome in the second quarter of 2019.
What's Next
Zynerba anticipates that its cash and cash equivalent position is sufficient to fund its operations and capital requirements beyond the expected submission and potential approval of ZYN002 in Fragile X Syndrome patients and into the first quarter of 2021.
SOURCE: https://www.benzinga.com/general/biotech/19/03/13335075/zynerba-pharmaceuticals-adds-autism-digeorge-syndrome-to-pipeline
Zynerba Pharmaceuticals Adds Autism, DiGeorge Syndrome To Pipeline
Alex Oleinic , Benzinga Staff Writer
March 11, 2019 12:57pm
Zynerba Pharmaceuticals Inc
ZYNE 1.26%
beat the consensus estimate for its fourth-quarter loss Monday and provided some highlights from its ongoing and upcoming trials.
What Happened
The company posted revenue of just $86,000 for the quarter ended Dec. 31, which was the only revenue recorded for the entire year. At the same time, Zynerba's net loss narrowed from $8.12 million or 60 cents per share a year earlier to $7.79 million or 44 cents per diluted share.
Zynerba registered an increase in general and administrative expenses during the fourth quarter from $2.38 million a year earlier to $3.26 million. Research and development costs declined from $5.83 million to $4.88 million. In this way, Zynerba's total operating expenses inched down from $8.2 million to $8.13 million.
The company ended the quarter with cash and cash equivalents of $59.8 million, down from $62.5 million recorded at the end of December 2017.
Why It's Important
Zynerba is conducting a number of studies evaluating its CBD-based transdermal gel candidate ZYN002, or Zygel.
The company said it is in the process of enrolling patients for its CONNECT-FX study that evaluates the efficacy and safety of Zygel in patients ages 3-17 with Fragile X syndrome. It expects to report top-line results from the study in the second half of 2019 and to submit a New Drug Application in the first half of 2020, with the potential for approval by the end of the year.
The Cannabis Capital Conference is coming back to Toronto! Click here to learn how you can join Tim Seymour, Jon Najarian, Alan Brochstein and many others.
Zynerba said it completed enrollment in BELIEVE 1, an open-label, multidose Phase 2 trial that evaluates Zygel in children and adolescents with developmental and epileptic encephalopathies. The top-line data from the study are expected in the third quarter of 2019.
Zynerba also said it initiated a study for Zygel administered to children and adolescents with autism spectrum disorder, and plans to initiate a study for Zygel in DiGeorge syndrome in the second quarter of 2019.
What's Next
Zynerba anticipates that its cash and cash equivalent position is sufficient to fund its operations and capital requirements beyond the expected submission and potential approval of ZYN002 in Fragile X Syndrome patients and into the first quarter of 2021.
source: https://www.benzinga.com/general/biotech/19/03/13335075/zynerba-pharmaceuticals-adds-autism-digeorge-syndrome-to-pipeline
Highest percentage gainer since Fri close. looks like it broke the resistance level at 9:03 EST. Was over sold 6 times throughout the day. There was a huge spike at 12:40 PM. Keep in mind it closed oversold. I'm expecting some profit taking 1st thing Monday morning. Will be interesting to see if it maintains staying above the resistance level throughout the day! Going to be watching this one very closely!